Lavelle Capital LP Reports Major Tech Holdings in 13F Filing
Lavelle Capital LP's recent 13F filing shows a strong focus on tech investments, reflecting industry trends towards growth sectors.
Northern Funds Delays ETF Registration Effectiveness
Northern Funds delays the effectiveness of its ETF registration until December 2, 2026, impacting investor expectations and the ETF market.
ARS X (SC VIII-A), L.P. Files New Investment Offering
ARS X (SC VIII-A), L.P. files a Form D with the SEC for a new investment offering, signaling growth in the pooled investment fund sector.
Barclays Bank announces AutoCallable Notes due in 2031
Barclays Bank PLC files a preliminary pricing supplement for AutoCallable Notes due November 12, 2031, indicating ongoing product diversification.
Hurricane Capital Advisors reveals latest investment holdings
Hurricane Capital Advisors LLC files 13F-HR, showcasing major investments in tech and healthcare sectors, including Apple and Amazon.
JPMorgan Chase Financial Co. announces $2.04M structured notes
JPMorgan Chase Financial Co. LLC files pricing supplement for $2.04M structured investments, signaling strategic growth in the national commercial banking sector.
BofA Finance LLC Files for Trigger Callable Yield Notes
BofA Finance LLC announces a new offering of Trigger Callable Yield Notes, linked to Russell 2000 and MSCI EAFE indices, guaranteed by Bank of America.
HUB Investment Partners reveals latest investment holdings
HUB Investment Partners, LLC discloses its latest investment holdings in a recent SEC filing, highlighting key sectors and strategies.
Hurricane Capital Advisors reports $410M in Q2 holdings
Hurricane Capital Advisors LLC's latest 13F-HR filing shows over $410 million in holdings, reflecting its investment strategy in the financial services sector.
Morgan Stanley Finance LLC Files Pricing Supplement for Securities
Morgan Stanley Finance LLC has filed a pricing supplement for Trigger PLUS securities linked to the S&P 500, enhancing its structured investment offerings.
BofA Finance LLC Files Preliminary Pricing for Yield Notes
BofA Finance LLC has filed a preliminary pricing supplement for Trigger Callable Yield Notes linked to major indices, fully guaranteed by Bank of America.
XPONANCE LLC Reports $17 Billion in Holdings as of Q3 2026
XPONANCE LLC reveals over $17 billion in holdings in its latest filing, showcasing a diverse investment portfolio as of September 30, 2026.
JPMorgan Chase Financial Co. files for new structured notes
JPMorgan Chase Financial Co. has filed a preliminary pricing supplement for new structured notes linked to the MerQube US Large-Cap Vol Advantage Index.
Bank of Nova Scotia Files Preliminary Pricing Supplement
The Bank of Nova Scotia files a preliminary pricing supplement for capped notes linked to the S&P 500 index, signaling a strategic move in the banking sector.
Morgan Stanley Finance LLC Unveils New Structured Securities
Morgan Stanley Finance LLC has filed a pricing supplement for its new Dual Directional Buffered PLUS securities, targeting investors seeking leveraged exposure to the Nasdaq-100 index.
Circle Internet Group reports insider stock sale by officer
Circle Internet Group, Inc. discloses the sale of 1,194 shares by officer Tamara L. Schulz, valued at approximately $87,233.64.
Amicus Financial Advisors reports $391.3M in latest 13F-HR
Amicus Financial Advisors, LLC reports a total portfolio value of $391.3 million in its latest 13F-HR filing, showcasing its investment strategy.
JPMorgan Chase Financial Co. unveils new structured notes
JPMorgan Chase Financial Co. LLC has filed for new structured investment notes linked to the MerQube US Large-Cap Vol Advantage Index, highlighting innovation in banking.
JPMorgan Chase Financial Co. announces $237,000 note offering
JPMorgan Chase Financial Co. has filed for $237,000 in Auto Callable Contingent Interest Notes linked to the MerQube US Large-Cap Vol Advantage Index.
de Verneuil Vanina sells 2,407 shares of Vir Biotechnology
de Verneuil Vanina sells 2,407 shares of Vir Biotechnology, totaling $26,717.70, reflecting trends in executive stock sales in the biotech sector.